Core Insights - BrightSpring Health Services' specialty pharmacy, Onco360®, has been selected as the national pharmacy partner for newly approved therapies targeting advanced cancers and rare genetic disorders [1][3]. Company Overview - BrightSpring Health Services offers integrated home- and community-based pharmacy and health solutions for complex populations, serving over 400,000 customers daily across all 50 states [4]. - Onco360® is a leading independent oncology pharmacy founded in 2003, focusing on the specialized needs of oncologists, patients, and healthcare providers [5]. New Therapy Partnerships - Onco360® will provide access, education, data, and expert support for innovative treatments for advanced ovarian and lung cancers, as well as neurofibromatosis type 1 [2][3]. - The therapies include GOMEKLI™ for neurofibromatosis type 1, AVMAPKI™ FAKZYNJA™ CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer, and IBTROZI™ for ROS1-positive non-small cell lung cancer [6].